Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, incomplete block, three period fixed
sequence crossover, multicenter, placebo-controlled study. The study will assess three oral
doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three
periods of 1-week duration each, with a 1-week washout period between treatment periods, in
subjects with diabetic or idiopathic gastroparesis.
Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic
gastroparesis by assessing changes in gastric emptying.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.